Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05065021
Title Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor
Recruitment Not yet recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto

fallopian tube cancer

peritoneum cancer

ovarian endometrial cancer

ovarian serous carcinoma


Bevacizumab + Dostarlimab-gxly + Niraparib

Bevacizumab + Niraparib

Bevacizumab + Dostarlimab-gxly + Paclitaxel

Age Groups: senior | adult
Covered Countries CAN

No variant requirements are available.